<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Canakinumab; Canakinumab; Ilaris" /><meta name="IX" content="Canakinumab; Ilaris" /><meta name="IXM" content="Canakinumab" /><title>CANAKINUMAB: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="208484.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="208484.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=208484.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4777.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="4789.htm">8.2.4 Other immunomodulating drugs</a> &gt; <a href="208475.htm">Canakinumab</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="208475.htm" title="Previous: Canakinumab">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="208498.htm#_208498" title="Next: Ilaris®">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a311026.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Canakinumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Other Miscellaneous Therapeutic Agents 92:92</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/24953-l.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Canakinumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: C &gt; Interactions of Canakinumab</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="208475.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Canakinumab</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs</p></div></li><li><a href="208498.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ilaris®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Canakinumab &gt; CANAKINUMAB</p></div></li></ul><ul><li><h3>BNF for Children (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/206598.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Canakinumab</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/206599.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">CANAKINUMAB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Canakinumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/206607.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ilaris®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Canakinumab &gt; CANAKINUMAB</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/24953-l.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Canakinumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/10573.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Canakinumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; C &gt; CA</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_208484">CANAKINUMAB</h1><?highlighter on?><div id="pC" class="jN"><div class="cAF"><h2>Indications</h2> <p class="cAF">see <a title="BNF:target-block: Canakinumab" href="208475.htm#_208480">notes above</a></p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">history of recurrent infection or predisposition to infection; monitor neutrophil count before starting treatment, 1–2 months after
starting treatment, and periodically thereafter; patients should receive all recommended vaccinations (including pneumococcal
and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs
risk—consult product literature and <a title="BNF:target-block: contra-indications" href="6451.htm#_6451.4">section 14.1</a> for further information</p><div class="cAV"><h3>Tuberculosis</h3> <p class="cAX">Patients should be evaluated
for latent and active tuberculosis before starting treatment and monitored
for signs and symptoms of tuberculosis during and after treatment</p></div></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">severe active infection (see also Cautions); neutropenia; concomitant use with tumour necrosis factor inhibitors (possible
increased risk of infections)</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">no information available</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">limited information available but manufacturer advises
no dose adjustment required</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">manufacturer advises avoid unless potential benefit
outweighs risk; effective contraception required during treatment
and for up to 3 months after last dose</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">consider if benefit outweighs risk—not known
if present in human milk</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">vertigo, increased susceptibility to infection,
injection-site reactions</p></div><div class="cAF"><h2>Dose</h2> <p class="cR"><span class="cU">By subcutaneous injection</span>, <span class="cAK">adult</span> and <span class="cAK">child</span> over
4 years, body-weight 15–40 kg, 2 mg/kg every 8 weeks; if response
inadequate 7 days after starting treatment, consider a second dose
of 2 mg/kg; if a full response is then achieved, subsequent dosing
should be 4 mg/kg every 8 weeks; body-weight over 40 kg, 150 mg every
8 weeks; if response inadequate 7 days after starting treatment, consider
a second dose of 150 mg; if a full response is then achieved,
subsequent dosing should be 300 mg every 8 weeks</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="208498.htm#_208498" title="Ilaris®">Ilaris®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="208475.htm">Previous: Canakinumab</a> | <a class="top" href="208484.htm#">Top</a> | <a accesskey="]" href="208498.htm#_208498" title="Ilaris®">Next: Ilaris®</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>